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REASONS FOR CONTINUING OR DISCONTINUING OLANZAPINE IN 
THE TREATMENT OF SCHIZOPHRENIA FROM PATIENTS’ AND 
CLINICIANS’ PERSPECTIVES
Chen J1, Ascher-Svanum H1, Case MG1, Nyhuis A1, Faries D1, Phillips G1, Perkins DO2, 
Hoffmann VP3
1Eli Lilly and Company, Indianapolis, IN, USA, 2University of North Carolina School of 
Medicine, Chapel Hill, NC, USA, 3Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: To identify the reasons for continuation or discontinuation of olan-
zapine in the treatment of schizophrenia from the patients’ and their clinicians’ per-
spectives. METHODS: Two measures were previously developed to assess the 
Reasons for Antipsychotic Discontinuation/Continuation (RAD), one from the 
patient’s perspective (RAD-I) and the other from patient’s clinician’s perspective 
(RAD-Q). These measures were administered to 199 outpatients with schizophrenia 
and their clinicians, participants in a 22-week open-label study of olanzapine. Reasons 
for continuation and for discontinuation of olanzapine were rated on a 5-point scale 
from “primary reason” to “not a reason.” The single most important reason was also 
identiﬁed. The top “primary reasons” for continuation and for discontinuation of 
olanzapine were identiﬁed. Levels of concordance between patients’ and clinicians’ 
reasons were assessed. RESULTS: Patients and clinicians have identiﬁed several 
primary reasons for continuation or discontinuation of olanzapine (2.3 to 8.5 reasons, 
on average). The top “primary reasons” for continuation on olanzapine were patient’s 
perception of improvement, improvement of positive symptoms, and improved func-
tioning. Study discontinuation rate was relatively low, and only a few of the discon-
tinued participants reported reasons for medication discontinuing. The top “primary 
reasons” for discontinuing olanzapine were: insufﬁcient improvement or worsening 
of positive symptoms, adverse events, and insufﬁcient improvement or worsening of 
negative symptoms. A high level of concordance was observed between patients’ and 
clinicians’ ratings. CONCLUSIONS: Medication efﬁcacy, especially for positive 
symptoms, appears to be the core driver of continuation on olanzapine and of its 
infrequent discontinuation. Reasons for medication discontinuation differ somewhat 
from reasons for continuation, with a high level of concordance between patients’ and 
clinicians’ perspectives.
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REFUSAL OF ANCILLARY SUPPORT SERVICES EARLY IN TREATMENT 
PREDICTS SIX MONTH OUTCOMES AMONG BUPRENORPHINE-
MEDICATION ASSISTED TREATMENT PATIENTS
Ruetsch C1, Tkacz J2
1Health Analytics LLC, Columbia, MD, USA, 2Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Multiple treatment options exist for chemical dependence patients 
including medication, counseling, and self-help groups. Prior research indicates that 
outcomes may be affected by choices patients make early in treatment. The purpose 
of this study was to examine patient differences among those who chose to participate 
in an ancillary patient support program early in opioid dependence (OD) treatment 
compared to those who chose not to. METHODS: OD patients new to B-MAT (N = 
1426) were randomized to receive B-MAT plus a patient support program (experi-
mental group, n = 987) or B-MAT alone (standard care, n = 439). The experimental 
group was divided into 2 groups based on patient choice: 1. refused to participate in 
the intervention (n = 336); 2. agreed to participate (n = 651). Subjects completed the 
Addiction Severity Index (ASI) at baseline, 1, 2, 3, and 6 months post-enrollment. The 
ASI is a semi-structured interview designed to measure problem severity in 7 functional 
areas known to be affected by alcohol and drug dependence. RESULTS: At month 
six, subjects who refused the intervention were less likely to be compliant with B-MAT 
(51.4%) compared to both the accepted intervention group (70.1%) and the standard 
care group (64.7%; χ2(2, n = 1062) = 25.24, p < .001). Further, at baseline, those 
who refused the intervention had lower legal, psychiatric, and family composite scores, 
which indicates lower problem severity in these areas, (p’s < .05) compared to experi-
mental cases who agreed to participate. CONCLUSIONS: Subjects who refused the 
intervention reported the lowest rate of B-MAT compliance at month six making 
refusal a potential triage indicator. However, as a group, refusers also reported lower 
problem severity in several functional areas at baseline compared to those who agreed 
to participate. Refusal of ancillary services alone is not an adequate triage indicator 
as refusals are heterogeneous in problem severity make-up.
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A LONGITUDINAL ANALYSIS OF THE EFFECT OF BUPRENORPHINE-
MEDICATION ASSISTED TREATMENT (B-MAT) AND A STRUCTURED 
PATIENT SUPPORT PROGRAM ON B-MAT ADHERENCE IN A 
NATIONAL SAMPLE OF OPIOID DEPENDENT PATIENTS
Ruetsch C1, Tkacz J2
1Health Analytics LLC, Columbia, MD, USA, 2Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: The purpose of this study was to examine the longitudinal effect of 
buprenorphine-medication assisted treatment (B-MAT), combined with a patient 
support program, on medication adherence in a sample of opioid dependent patients. 
Its effect on drug abuse will also be explored. METHODS: OD patients new to 
B-MAT (N = 410) were randomized to receive B-MAT plus a patient support program 
(experimental group, n = 249) or B-MAT alone (standard care, n = 161). All patients 
completed the Addiction Severity Index (ASI) at baseline, 1, 2, 3, and 6 months post-
enrollment. The ASI is a semi-structured interview designed to measure problem 
severity in 7 functional areas known to be affected by alcohol and drug dependence. 
A repeated measures ANOVA was used to detect group, time and interaction effects 
for compliance with B-MAT. RESULTS: One year follow-up data will be presented 
in the poster; however, only 6 month data were available at the time of submission. 
The intervention group reported taking their medication on more days than controls 
F(1408) = 4.48; p < 0.05). A signiﬁcant time effect was also observed F(3, 1224) = 
36.9, p < 0.001), with subjects as a whole taking their medication on less days as the 
study progressed. The signiﬁcant time x group interaction indicated that subjects in 
the control group took their medication on less days over the course of the study 
compared to the intervention group (F(3, 1224) = 2.34, p < 0.10). Greater involvement 
in the intervention also led to reductions in opioid abuse (p < 0.05). CONCLUSIONS: 
The patient support program seemed to improve the number of days OD patients took 
their medication and reduced the likelihood of abusing drugs. Supplementing B-MAT 
with a structured compliance-enhancement program may be an effective way to 
improve adherence with medication in a sample of OD patients.
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THE EFFECT OF A TELEPHONIC PATIENT SUPPORT PROGRAM ON 
TREATMENT OUTCOMES AMONG A SAMPLE OF OPIOID DEPENDNCE 
PATIENTS: ONE YEAR FOLLOW-UP
Ruetsch C1, Tkacz J2
1Health Analytics LLC, Columbia, MD, USA, 2Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is clinically 
effective for opioid dependence (OD). However, participation in ancillary treatment 
activities may enhance medication compliance, thereby improving treatment out-
comes. The purpose of the present study was to investigate the effect of a telephonic 
patient compliance-enhancement program on B-MAT compliance in a sample of OD 
patients after one year in treatment. METHODS: OD patients new to B-MAT (N = 
1426) were randomized to receive B-MAT plus the telephonic patient support program 
(intervention group) or B-MAT alone (standard care group). Patients completed the 
Addiction Severity Index (ASI) at the time of enrollment and at 5 follow-up periods 
over the course of one year. The ASI is a semi-structured interview designed to measure 
problem severity in 7 functional areas known to be affected by alcohol and drug 
dependence. RESULTS: One year follow-up data will be presented in the poster; 
however, only 6 month data were available at the time of submission. The intervention 
group was signiﬁcantly more compliant with B-MAT than the standard care group 
(73.3% vs. 64.7%, χ2 = 6.43, p = 0.01). Furthermore, greater involvement in the 
intervention led to a reduction in the use of injection and prescription opioids (p’s < 
0.05). CONCLUSIONS: The compliance-enhancement intervention improved adher-
ence to B-MAT and patient treatment including abuse of opioids. Supplementing 
B-MAT with a structured, telephonic compliance-enhancement program is an effective 
way to improve compliance with medication as well as patient outcomes.
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OPIOID RELAPSE RATES AMONG A SAMPLE OF NEW 
BUPRENORPHINE-MEDICATION ASSISTED TREATMENT PATIENTS: 
RELATIONSHIP TO MEDICATION COMPLIANCE AT ONE YEAR
Ruetsch C1, Tkacz J2
1Health Analytics LLC, Columbia, MD, USA, 2Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Studies consistently show high relapse rates (25%–35%) among chemi-
cal dependence patients. Relapse is especially problematic for patients diagnosed with 
opioid dependence (OD), which has often been characterized as a chronic relapsing 
disorder. The purpose of the present study was to examine the effect of compliance 
with buprenorphine-medication assisted treatment (B-MAT) on relapse among a 
sample of opioid dependent patients. METHODS: OD patients new to B-MAT (N = 
554) completed the Addiction Severity Index (ASI) at baseline, 1, 2, 3, and 6 months 
post-enrollment. The ASI is a semi-structured interview designed to measure problem 
severity in 7 functional areas known to be affected by alcohol and drug dependence. 
One year follow-up data will be presented in the poster; however, only 6 month data 
were available at the time of submission. Compliance with B-MAT was deﬁned as 
taking medication on at least 80% of the days over the past month. Relapse was 
deﬁned as use of opioids, including heroin, methadone, or pharmaceutical opioids, 
after an initial period of no use. RESULTS: Patients who were compliant with B-MAT 
were signiﬁcantly less likely to relapse compared to subjects who were non-compliant 
with B-MAT (24.8% vs. 57.8%, χ2(1, n = 493) = 37.49, p < 0.001). Differences in 
baseline characteristics between the compliance groups and the relapse groups were 
also revealing. Patients who relapsed had signiﬁcantly higher baseline medical, legal, 
psychiatric, and family composites scores compared to those who did not relapse (p’s 
< 0.05), indicating greater problem severity in these areas. CONCLUSIONS: Compli-
ance with B-MAT for six months seems to reduce the likelihood of relapse in OD 
patients. Difference in patient characteristics may be used to help providers identify 
patients who need higher levels of care to avoid relapse. Future studies should examine 
relapse rates in patients who have successfully tapered off B-MAT.
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ISSUES IN THE USE OF THE HOSPITAL ANXIETY AND DEPRESSION 
SCALE IN AN ALCOHOL-DEPENDENT POPULATION
McPherson A, Martin CR
University of the West of Scotland, Ayr, UK
OBJECTIVES: To evaluate the psychometric properties of the Hospital Anxiety and 
Depression Scale (HADS) in selected research to ascertain the suitability of this tool 
for screening for anxiety and depression in an alcohol-dependent population. 
METHODS: Narrative review. RESULTS: Of the 529 articles initially evaluated, 
selected studies included 28 studies used to evaluate the factor analysis of the HADS, 
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5 studies were selected that reported appropriate data to assess test-retest reliability 
and 26 studies were selected which reported alpha coefﬁcient scores to determine the 
internal consistency of the HADS. Factor analysis studies revealed consistent bi-
dimensional or tripartite models, with few exceptions. Just one study of ﬁve evaluated 
fulﬁlled he criteria for good test-retest reliability. However, most of the studies report-
ing alpha revealed an acceptable level of internal consistency reliability. CONCLU-
SIONS: Based on the studies in the review, the ﬁndings suggest that the HADS may 
be an effective screening tool in an alcohol dependent population, though there is a 
caveat to this. The test-retest characteristics appear unsatisfactory in the studies 
selected. Notwithstanding the test-retest reliability characteristics, factor structure and 
internal consistency evidence would suggest the instrument to be suitable for use in 
an alcohol-dependent population.
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CONCORDANCE OF COMPUTERIZED SELF-REPORT MEASURES OF 
DSM-IV-TR MOOD AND ANXIETY DISORDERS COMPARED TO GOLD 
STANDARD CLINICAL ASSESSMENTS IN PRIMAY CARE
Kessler RC1, Farley PA2, Gruber M1, Harshaw Q2, Jewell MA2, Sampson N1, 
Shillington AC2
1Harvard Medical School, Boston, MA, USA, 2EPI-Q Inc, Oak Brook, IL, USA
OBJECTIVES: Substantial numbers of patients presenting to primary care suffer 
unrecognized disorders of mood or anxiety, potentially complicating treatment and 
outcome. The objective of this study was to evaluate the validity of an electronic 
screening instrument based upon the World Health Organization’s Composite Inter-
national Diagnostic Interview (WHO CIDI) and DSM-IV-TR designed for use in 
primary care. This is a fully-structured computerized instrument designed to screen 
for bipolar disorder (BPD), generalized anxiety disorder (GAD), panic disorder (PD) 
and major depressive episodes (MDE) in primary care patients. METHODS: A pre-
liminary version of the instrument was piloted in individuals with known disease. 
Following cognitive interviews with subjects, it was reﬁned and tested in 3058 respon-
dents from 29 primary care physician ofﬁces across the US. Sub-samples were selected 
to receive a reappraisal interview (n = 206), over-sampling on those screening positive 
for either the disorders. To assess validity each completed a “gold-standard” Struc-
tured Clinical Interview for DSM (SCID) administered via phone by trained clinicians. 
RESULTS: Individual-level concordance was good between the screener diagnoses and 
the SCID assessments. Area under the receiver operating characteristic curve (AUC), 
a measure of classiﬁcation accuracy not inﬂuenced by disorder prevalence) demon-
strated substantial agreement for MDE (AUC = 0.85). BPD initially demonstrated 
fair-moderate agreement (AUC = .78), but this was improved to the “substantial” 
range (AUC = 0.86) with the enhancement of history of lifetime mania in the SCID 
interview. PD and GAD both demonstrated fair-moderate agreement (AUC = 0.79 
and AUC = 0.67; respectively). CONCLUSIONS: The results demonstrate that the 
CIDI-based computerized screening instrument can be used to identify the vast major-
ity of patients with a high likelihood of mood and anxiety disorders treated in the 
primary care setting.
PMH73
EVALUATION OF PSYCHOMETRIC EQUIVALENCE BETWEEN 
INTERACTIVE VOICE-RESPONSE (IVR) AND PAPER VERSIONS OF 
DAILY ASSESSMENT SCALE FOR ANXIETY (DAS-A)
Mundt J1, Hassan M2, Lappalainen J2, Morlock R3
1Healthcare Technology Systems, Inc., Madison, WI, USA, 2AstraZeneca, Wilmington, DE, 
USA, 3i3 Innovus, Santa Monica, CA, USA
OBJECTIVES: The DAS-A is an 8-item patient-reported instrument designed to detect 
daily changes of anxiety symptoms in patients with Generalized Anxiety Disorder 
(GAD) during the ﬁrst week of treatment. This study compared the psychometric and 
measurement properties of an IVR version of the DAS-A with the original paper 
version. METHODS: Adult patients with GAD were enrolled at the screening visit of 
a clinical trial. Treatment randomization occurred at day 0. Patients were scheduled 
to complete the IVR DAS-A from day −6 through day 7. Paper-and-pencil DAS-A 
forms were completed by selected patients during clinic visits on days 0, 4 and 7. 
Psychometric properties of both DAS-A forms were compared with respect to internal 
scale consistency (Chronbach’s alpha), item reliability (intraclass correlation coefﬁ-
cient; ICC), and mean score equivalence when both formats were administered within 
24 hours of each other (paired t-tests). RESULTS: A total of 2804 IVR DAS-A assess-
ments and 119 paper DAS-A forms were completed. In 62 instances both formats 
were completed within 24 hours of one another. Cronbach’s alpha across all IVR 
DAS-A administrations was 0.85; the mean ICC was 0.84 (95% CI = 0.83–0.85). 
Cronbach’s alpha across all paper DAS-A administrations was 0.90; the mean ICC 
was 0.89 (95% CI = 0.86–0.92). The mean (± SD) IVR and paper DAS-A total scores 
were 58.97 (± 20.09) and 60.91 (± 21.00), respectively; this difference was not statisti-
cally signiﬁcant, t = 1.89, p. = 0.06. The correlation between the DAS-A total scores 
was 0.90, p. < 0.001. Comparisons between DAS-A formats at an item-by-item level 
found signiﬁcant inter-method correlations (range 0.59 to 0.79); one item identiﬁed a 
potentially signiﬁcant difference in mean score, t = 2.05, p. = 0.04, but likely reﬂects 
Type I error inﬂation. CONCLUSIONS: This analysis supports the equivalence of the 
IVR and paper DAS-A formats for measuring daily changes of anxiety symptoms in 
patients with GAD.
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INTENSIVE COGNITIVE INTERVIEWING WITH PATIENTS DIAGNOSED 
WITH SCHIZOPHRENIA AND THE REFINEMENT OF THE CLEAR 
THINKING SCALE (CTS)
Bridges JF1, White SM2
1Johns Hopkins University, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public 
Health, Baltimore, MD, USA
OBJECTIVES: Intensive cognitive interviews are valuable in the reﬁnement of patient 
reported outcome (PRO) instruments and can identify how patients perceive the 
meaning of questions, how they develop and justify their responses and can allow the 
researcher to test face validity and burden of the instrument. We conducted intensive 
cognitive interviews with outpatients diagnosed with schizophrenia to reﬁne the clear 
thinking scale (CTS)—a recently validated PRO instrument that assesses patient prefer-
ences and functioning across four sub-domains (staying organized; making sense of 
the world; feeling clear headed; and expressing thoughts and feelings). METHODS: 
Intensive cognitive interviews were conducted by an experienced interviewer at various 
facilities associated with Johns Hopkins. Following the consenting process, partici-
pants completed the preferences (5 items) and functioning (28 items) components of 
the CTS. Concurrent and retrospective verbal probing was utilized to assess the 
respondent level of understanding and burden. All interviews were recorded, tran-
scribed and analyzed using phenomenological qualitative methods. RESULTS: A total 
of 20 patients with a primary diagnosis of diagnosis of schizophrenia or schizoaffective 
disorder participated in the study. While respondents regularly got off topic and often 
lacked conﬁdence in their answers, we found a relatively consistent interpretation of 
items across respondents. We also identiﬁed several approaches to improving the CTS 
scale, including: 1) simplifying items and avoiding compounded items; 2) repeating 
the time frame (i.e., in the past week) before every question; 3) supporting response 
variables with numbers/details; 4) using rankings rather than ratings to elicit patient 
preferences; 5) avoiding items that might have a literal interpretation; 6) measuring 
functioning prior to measuring preferences; and 7). having an example question for 
both functioning and preferences questions. CONCLUSIONS: Despite its difﬁculties, 
intensive cognitive interviewing among patients diagnosed with schizophrenia pro-
vided valuable information for the reﬁnement of the CTS and other future PRO scales.
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EFFECT OF EQUIVALENT AND NON-EQUIVALENT SUBSTITUTION OF 
PRESCRIBED DRUGS FOR DEPRESSION AND ANXIETY DISORDERS ON 
PATIENTS’ TREATMENT ADHERENCE AND PERCEPTION
LaPensee K1, Carson R1, Werner P1, Sexton CC2, Gelhorn H2, Stankus A3, Erder H1
1Forest Research Institute, Jersey City, NJ, USA, 2United BioSource Corporation, Bethesda, 
MD, USA, 3KantarHealth, Princeton, NJ, USA
OBJECTIVES: To assess the impact of “equivalent substitution” (true generic of the 
prescribed drug) or “non-equivalent substitution” (switch to another agent, brand or 
generic) on perceptions, attitudes, and treatment adherence in patients with and 
without depression and anxiety disorder. METHODS: Over 10,000 randomly-selected 
US respondents from the 2007 National Health and Wellness Survey (NWHS) com-
pleted a self-administered, internet-based survey. The subpopulation of 2360 self-
identiﬁed anxious/depressed respondents was supplemented with 5539 re-contacted 
self-identiﬁed anxious/depressed responders from the 2006/2007 NWHS. Responses 
from non-anxious/depressed patients were compared to those of self-identiﬁed 
anxious/depressed patients using t-tests, ANOVA, and multiple linear and logistic 
regressions. Comparisons were also made between anxious/depressed subgroups. 
RESULTS: A total of 52% of non-anxious/depressed patients experienced therapeutic 
substitution; 50% reported equivalent and 18% to non-equivalent substitutions (dif-
ferent brand—10%, generic of another agent—8%). 51% of the non-anxious/
depressed and 71.5% of the anxious/depressed patients have experienced switching. 
More anxious/depressed patients found required step therapy unacceptable (P < 0.001; 
many tried to change health plans for this reason.77% of non-anxious/depressed and 
81% of anxious/depressed patients considered equivalent substitution (an equivalent 
generic) acceptable, but only about half in both groups thought that non-equivalent 
substitution was acceptable. Substitution affected attitudes and treatment adherence 
signiﬁcantly more in anxious/depressed vs. non-anxious/depressed patients. Impor-
tantly, anxious/depressed patients subjected to non-equivalent substitution reported 
signiﬁcantly lower treatment adherence than those who were not (P < 0.001). Switch-
ing to a non-equivalent generic also reduced adherence more than switching to an 
equivalent generic (P < 0.0001) in this population. CONCLUSIONS: About half of 
all respondents found required step therapy unacceptable. Anxious/depressed patients 
reported signiﬁcant deterioration of treatment adherence and treatment-related atti-
tudes following equivalent, and especially non-equivalent substitution. Substitution of 
prescribed drugs for depression or anxiety disorders negatively affected self-reported 
treatment adherence in the treated population, which may impact treatment 
outcomes.
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FUNCTIONAL IMPAIRMENT IN CHILDREN AND ADOLESCENTS  
WITH DEPRESSION
Nagar S1, Aparasu RR2, Chen H2, Sherer J2
1Abt Bio-Pharma Solutions Inc., Lexington, MA, USA, 2University of Houston, Houston, 
TX, USA
OBJECTIVES: This study examined the extent of functional impairment in children 
and adolescents aged 5 to 17 years with depression based on 2005–2006 Medical 
Expenditure Panel Survey (MEPS) data. METHODS: This study involved retrospective 
